Summary

Results from the Combination Therapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma trial [EURAMOS-1; NCT00134030; J Clin Oncol 2013 (suppl; abstr LBA10504)] show that maintenance therapy with pegylated interferon a-2b (PEG IFN-a-2b) after surgery and chemotherapy does not improve event-free survival in patients with high-grade osteosarcoma and good response to preoperative methotrexate, doxorubicin, and cisplatin (regimen collectively called MAP).